Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1992 2
1993 4
1994 1
1995 2
1997 2
1998 1
2003 1
2005 1
2006 1
2007 1
2009 1
2010 2
2012 2
2013 1
2014 2
2015 2
2016 1
2017 7
2018 5
2019 3
2020 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR, Åvall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, Anttila M, Werner TL, Lund B, Lindahl G, Hietanen S, Peen U, Dimoula M, Roed H, Ør Knudsen A, Staff S, Krog Vistisen A, Bjørge L, Mäenpää JU; AVANOVA investigators. Mirza MR, et al. Among authors: maenpaa ju. Lancet Oncol. 2019 Oct;20(10):1409-1419. doi: 10.1016/S1470-2045(19)30515-7. Epub 2019 Aug 29. Lancet Oncol. 2019. PMID: 31474354 Clinical Trial.
Reply.
Mäenpää MM, Nieminen K, Mäenpää JU. Mäenpää MM, et al. Among authors: maenpaa ju. Am J Obstet Gynecol. 2017 Jun;216(6):619-620. doi: 10.1016/j.ajog.2017.01.033. Epub 2017 Jan 29. Am J Obstet Gynecol. 2017. PMID: 28143701 No abstract available.
Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas.
Hensley ML, Barrette BA, Baumann K, Gaffney D, Hamilton AL, Kim JW, Maenpaa JU, Pautier P, Siddiqui NA, Westermann AM, Ray-Coquard I. Hensley ML, et al. Among authors: maenpaa ju. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S61-6. doi: 10.1097/IGC.0000000000000261. Int J Gynecol Cancer. 2014. PMID: 25341583 Free PMC article. Review.
Urinary Polyamines as Biomarkers for Ovarian Cancer.
Niemi RJ, Roine AN, Häkkinen MR, Kumpulainen PS, Keinänen TA, Vepsäläinen JJ, Lehtimäki T, Oksala NK, Mäenpää JU. Niemi RJ, et al. Among authors: maenpaa ju. Int J Gynecol Cancer. 2017 Sep;27(7):1360-1366. doi: 10.1097/IGC.0000000000001031. Int J Gynecol Cancer. 2017. PMID: 28604456
Cesarean scar defect: a prospective study on risk factors.
Antila-Långsjö RM, Mäenpää JU, Huhtala HS, Tomás EI, Staff SM. Antila-Långsjö RM, et al. Among authors: maenpaa ju. Am J Obstet Gynecol. 2018 Nov;219(5):458.e1-458.e8. doi: 10.1016/j.ajog.2018.09.004. Epub 2018 Sep 18. Am J Obstet Gynecol. 2018. PMID: 30240650
Tumor cell-specific Serpin A1 expression in vulvar squamous cell carcinoma.
Lagerstedt M, Huotari-Orava R, Nyberg R, Nissinen L, Farshchian M, Laasanen SL, Snellman E, Mäenpää JU, Kähäri VM. Lagerstedt M, et al. Among authors: maenpaa ju. Arch Gynecol Obstet. 2019 May;299(5):1345-1351. doi: 10.1007/s00404-018-5015-y. Epub 2019 Jan 4. Arch Gynecol Obstet. 2019. PMID: 30607583 Free PMC article.
45 results